FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379340227> ?p ?o ?g. }

• W4379340227 endingPage "10027" @default.
• W4379340227 startingPage "10027" @default.
• W4379340227 abstract "10027 Background: Patients (pts) with cHL with SER to initial chemo are at higher risk of relapse, and chemo dose intensification and radiotherapy (RT) can increase the burden of late organ toxicities. The open-label, phase 2 KEYNOTE-667 study (NCT03407144) is evaluating pembro plus chemo in pts with cHL and SER to front-line chemo. Results of an interim analysis in pts with high-risk cHL (group 2) and SER are presented. Methods: Pts were aged 3-17 (children) or 18-25 y (young adults) with newly diagnosed stage IIEB, IIIEA, IIIEB, IIIB, IVA, or IVB cHL. Pts received induction with 2 cycles of vincristine, etoposide, prednisone/prednisolone, and doxorubicin (OEPA). Response was assessed after induction (early) and consolidation (late) therapy by PET/MRI/CT. After induction, pts with rapid early response at the early response assessment (ERA) received nonstudy therapy and pts with SER at ERA received consolidation with 4 cycles cyclophosphamide, vincristine, prednisone/prednisolone, dacarbazine (COPDAC-28) plus pembro 2 mg/kg up to 200 mg IV every 3 weeks (Q3W; aged 3-17 y) or 200 mg IV Q3W (aged 18-25 y). Pts with PET positivity (Deauville score 4-5) after consolidation (late response assessment [LRA]), received involved-site RT (28.8 Gy) to late PET-positive residua; RT was omitted in pts with PET negativity. All pts with SER received maintenance pembro Q3W for a total of 17 doses. Primary end point was ORR by blinded independent central review (BICR) per Cheson 2007 International Working Group criteria in pts with SER. Secondary end points included PET negativity after consolidation and safety. Results: At data cutoff (Sep 02, 2022), median follow-up was 15.3 mo (range, 3.2-30.5); 49 pts with high-risk cHL with SER were included. Median age was 15 y (range, 6-22), 24 (49%) pts had bulky disease, and 31 (63%) had Ann Arbor stage IV disease. 22 (45%) pts completed treatment and 24 (49%) were ongoing on consolidation/maintenance treatment. Median time on pembrolizumab was 10.4 mo (range, 0.5-11.8). 42 (86%) of 49 pts had a LRA, of whom 27 (64%) were PET negative by BICR (30 [71%] PET negative by investigator). All-cause adverse events (AEs) occurred in 42 (86%) pts, with 30 (61%) having a treatment-related AE. Grade ≥3 AEs occurred in 13 (27%) pts, with 7 (14%) having a serious AE. Grade ≥3 treatment-related AEs occurred in 6 (12%) pts. 4 (8%) pts had immune-mediated AEs (2 grade 1 hypothyroidism; 2 grade 2 hypothyroidism). Conclusions: In pediatric pts with high-risk cHL and SER to standard OEPA induction, pembro plus COPDAC-28 consolidation had manageable safety and resulted in 64% of pts having a PET-negative response at end of chemo and being spared RT. These results suggest adding pembro to COPDAC-28 consolidation may augment responses in this high-risk population. Clinical trial information: NCT03407144 ." @default.
• W4379340227 created "2023-06-05" @default.
• W4379340227 creator A5000858647 @default.
• W4379340227 creator A5022021296 @default.
• W4379340227 creator A5029964677 @default.
• W4379340227 creator A5038208984 @default.
• W4379340227 creator A5038785600 @default.
• W4379340227 creator A5042346885 @default.
• W4379340227 creator A5043875113 @default.
• W4379340227 creator A5051979326 @default.
• W4379340227 creator A5061665043 @default.
• W4379340227 creator A5073707704 @default.
• W4379340227 creator A5074761737 @default.
• W4379340227 creator A5076859301 @default.
• W4379340227 creator A5078335763 @default.
• W4379340227 creator A5079274311 @default.
• W4379340227 creator A5086252694 @default.
• W4379340227 creator A5087994445 @default.
• W4379340227 date "2023-06-01" @default.
• W4379340227 modified "2023-10-16" @default.
• W4379340227 title "Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study." @default.
• W4379340227 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.10027" @default.
• W4379340227 hasPublicationYear "2023" @default.
• W4379340227 type Work @default.
• W4379340227 citedByCount "1" @default.
• W4379340227 countsByYear W43793402272023 @default.
• W4379340227 crossrefType "journal-article" @default.
• W4379340227 hasAuthorship W4379340227A5000858647 @default.
• W4379340227 hasAuthorship W4379340227A5022021296 @default.
• W4379340227 hasAuthorship W4379340227A5029964677 @default.
• W4379340227 hasAuthorship W4379340227A5038208984 @default.
• W4379340227 hasAuthorship W4379340227A5038785600 @default.
• W4379340227 hasAuthorship W4379340227A5042346885 @default.
• W4379340227 hasAuthorship W4379340227A5043875113 @default.
• W4379340227 hasAuthorship W4379340227A5051979326 @default.
• W4379340227 hasAuthorship W4379340227A5061665043 @default.
• W4379340227 hasAuthorship W4379340227A5073707704 @default.
• W4379340227 hasAuthorship W4379340227A5074761737 @default.
• W4379340227 hasAuthorship W4379340227A5076859301 @default.
• W4379340227 hasAuthorship W4379340227A5078335763 @default.
• W4379340227 hasAuthorship W4379340227A5079274311 @default.
• W4379340227 hasAuthorship W4379340227A5086252694 @default.
• W4379340227 hasAuthorship W4379340227A5087994445 @default.
• W4379340227 hasConcept C121608353 @default.
• W4379340227 hasConcept C126322002 @default.
• W4379340227 hasConcept C141071460 @default.
• W4379340227 hasConcept C143998085 @default.
• W4379340227 hasConcept C2776694085 @default.
• W4379340227 hasConcept C2776755627 @default.
• W4379340227 hasConcept C2777701055 @default.
• W4379340227 hasConcept C2778720950 @default.
• W4379340227 hasConcept C2779429289 @default.
• W4379340227 hasConcept C2780057760 @default.
• W4379340227 hasConcept C2780964509 @default.
• W4379340227 hasConcept C2989005 @default.
• W4379340227 hasConcept C71924100 @default.
• W4379340227 hasConceptScore W4379340227C121608353 @default.
• W4379340227 hasConceptScore W4379340227C126322002 @default.
• W4379340227 hasConceptScore W4379340227C141071460 @default.
• W4379340227 hasConceptScore W4379340227C143998085 @default.
• W4379340227 hasConceptScore W4379340227C2776694085 @default.
• W4379340227 hasConceptScore W4379340227C2776755627 @default.
• W4379340227 hasConceptScore W4379340227C2777701055 @default.
• W4379340227 hasConceptScore W4379340227C2778720950 @default.
• W4379340227 hasConceptScore W4379340227C2779429289 @default.
• W4379340227 hasConceptScore W4379340227C2780057760 @default.
• W4379340227 hasConceptScore W4379340227C2780964509 @default.
• W4379340227 hasConceptScore W4379340227C2989005 @default.
• W4379340227 hasConceptScore W4379340227C71924100 @default.
• W4379340227 hasIssue "16_suppl" @default.
• W4379340227 hasLocation W43793402271 @default.
• W4379340227 hasOpenAccess W4379340227 @default.
• W4379340227 hasPrimaryLocation W43793402271 @default.
• W4379340227 hasRelatedWork W1896861650 @default.
• W4379340227 hasRelatedWork W1921119956 @default.
• W4379340227 hasRelatedWork W1986487042 @default.
• W4379340227 hasRelatedWork W2004932524 @default.
• W4379340227 hasRelatedWork W2017046780 @default.
• W4379340227 hasRelatedWork W2031021461 @default.
• W4379340227 hasRelatedWork W2044362603 @default.
• W4379340227 hasRelatedWork W2047206303 @default.
• W4379340227 hasRelatedWork W2138201596 @default.
• W4379340227 hasRelatedWork W2143831053 @default.
• W4379340227 hasVolume "41" @default.
• W4379340227 isParatext "false" @default.
• W4379340227 isRetracted "false" @default.
• W4379340227 workType "article" @default.